NGM Biopharmaceuticals (NGM) PT Raised to $36 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Raymond James Upgrades NGM Biopharmaceuticals (NGM) to Strong Buy; 'Complement Validated in GA'
September 12, 2021 9:58 PM EDTRaymond James analyst Steven Seedhouse upgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Outperform to Strong Buy with a price target of $39.00.
The analyst commented, "Phase 3 data for Apellis pegcetacoplan in GA provide strong evidence that complement inhibition is an active mechanism in... More



